

OA Product & Service Agreements

Oncology Associates offers a diverse portfolio of major pharmaceutical manufacturers' products at favorable prices to our members. In addition, OA offers several practice management services. Please see the list below for descriptions and contact information for our manufacturer and service agreements.

Amgen

800.447.1000

Products: Aranesp, Neulasta, Neupogen

Aspen Consulting Group LTD

877.238.7032

Specializes in the independent assessment of healthcare practice **internal controls, operations and management**

Aventis

800.996.6626

(Reimbursement Hotline)

Products: Anzemet, Taxotere

Bedford Labs

800.562.4797

Offers an entire suite of **generic drugs** including but not limited to: Cisplatin, Cladribine, Doxorubicin, Leucovorin, Paclitaxel, Pamidronate

GlaxoSmithKline

888.825.5249

Products: Hycamtin, Navelbine, Zofran

Medical Specialties

800.967.6400

Rental of oncology infusion pumps

MedImmune Oncology, Inc.

877.633.4411

Product: Ethyol

MDinTouch

866.774.0002

Web-based **dictation and transcription**

MGI PHARMA, INC.

866.302.5694

(Reimbursement Hotline)

Product: Aloxi

Novartis Oncology

877.527.4357

Products: Sandostatin LAR, Zometa

Novidea Healthcare

877.503.1455

Professional Employer Organization for healthcare providers.

Ortho Biotech

800.325.7504

Product: Procrit

Pharmion

720.564.9100

Products: Innohep, Vidaza

Roche, Inc.

973.235.5000

Product: Kytril, XELODA

SICOR

800.729.9991

Products: Aducril, Carboplatin Injection, Carboplatin for Injection, Fludarabine, Fludarabine Phosphate Injection, IDArubicin Injection, Ifosfamide/Mesna Kit, Leuprolide Acetate, Mesna Injection, Vinorelbine Tartrate Injection

Wyeth/Genetics Institute

617.876.1170

Product: Neumega



Sandostatin LAR® Rebates Released

As part of the OA product agreement for Sandostatin LAR®, we are pleased to announce the release of June and July 2004 rebate checks. Eligible members should have already received these checks, as they were issued on October 11, 2004 (June) and October 28, 2004 (July).

Rebates are earned on a monthly basis with the resulting checks sent to the practice at approximately 90 days from the end of each month.

Contact Oncology Associates at 888-732-7352 with any questions regarding the rebates earned.

Maximum Sandostatin LAR Contract Benefit available:

- > April '04-December '04
- > 5.0% Discount
- > 3.0% Performance Rebate
- > 8.0% Maximum Benefit

ZOMETA® Agreement Reminder

Are you getting the most out of the OA agreement with Novartis? ZOMETA® (zoledronic acid) was added to the Novartis agreement **October 1, 2004.**

ZOMETA® is offered to all OA members in good standing at a significant **discount of 5%**. The product is available in 4 mg/5ml vials.

ZOMETA® Injection is indicated for the treatment of hypercalcemia of malignancy. ZOMETA® is also indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

Contact Oncology Associates at **888-732-7352** with any questions about the Novartis agreement. For more information about ZOMETA®, visit **www.zometa.com**.

ZOMETA® Contract Details

Product Name	Strength	NDC#	Vials/pkg	% Discount
Zometa®	4 mg/5 ml vial	0078-0387-25	1	5%